304 related articles for article (PubMed ID: 34844296)
1. Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.
Tufan A; Matucci-Cerinic M
Turk J Med Sci; 2021 Dec; 51(SI-1):3391-3404. PubMed ID: 34844296
[TBL] [Abstract][Full Text] [Related]
2. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.
Tufan A; Avanoğlu Güler A; Matucci-Cerinic M
Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Licciardi F; Giani T; Baldini L; Favalli EG; Caporali R; Cimaz R
Pediatr Rheumatol Online J; 2020 Apr; 18(1):35. PubMed ID: 32321540
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
7. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini P; Giorgi V; Sirotti S; Marotto D; Ardizzone S; Rizzardini G; Antinori S; Galli M
Clin Exp Rheumatol; 2020; 38(2):337-342. PubMed ID: 32202240
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
9. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
10. Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.
Jung HE; Lee HK
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834939
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
12. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
15. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
16. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Palma G; Pasqua T; Silvestri G; Rocca C; Gualtieri P; Barbieri A; De Bartolo A; De Lorenzo A; Angelone T; Avolio E; Botti G
Front Immunol; 2020; 11():2094. PubMed ID: 32973818
[TBL] [Abstract][Full Text] [Related]
17. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
18. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?
Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L
Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757
[TBL] [Abstract][Full Text] [Related]
19. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
Khan M; Adil SF; Alkhathlan HZ; Tahir MN; Saif S; Khan M; Khan ST
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
